NASDAQ:MNTA
Delisted
Momenta Pharmaceuticals Stock News
$52.48
+0 (+0%)
At Close: May 27, 2022
J&J’s $6.5 Billion Momenta Pact Is Year’s Biggest Pharma Deal
12:37pm, Wednesday, 19'th Aug 2020
(Bloomberg) -- Johnson & Johnson agreed to pay $6.5 billion in cash to acquire Momenta Pharmaceuticals Inc., a maker of autoimmune-disease drugs, in the largest pharmaceutical-industry merger this yea
5 things to know before the stock market opens Wednesday
12:21pm, Wednesday, 19'th Aug 2020
The S&P 500 was pacing to add to Tuesday's record close as Target and Lowe's reported blowout earnings.
J&J strikes $6.5 billion deal for autoimmune disease specialist Momenta
12:08pm, Wednesday, 19'th Aug 2020
The deal gives J&J's Janssen unit access to Momenta's experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles, and other diseases
Stocks making the biggest moves in the premarket: Target, Lowe's, J&J, Momenta, Gilead & more
12:01pm, Wednesday, 19'th Aug 2020
The stocks making the biggest moves in premarket trading include Target, Lowe's, J&J, Momenta, Gilead, and more.
(MNTA) Alert: Johnson Fistel Investigates Proposed Sale of Momenta Pharmaceuticals; Are Shareholders Getting a Fair Price?
11:38am, Wednesday, 19'th Aug 2020
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc. ("Momenta" or the "Company") (NASDAQ: MNTA) breached their
JNJ To Buy Momenta Pharma In $6.5B All-Cash Deal; MNTA Up 70%
11:21am, Wednesday, 19'th Aug 2020
Johnson & Johnson (JNJ) has agreed to buy Momenta Pharma (MNTA), a biotech focused on discovering and developing novel biologic therapeutics for rare immune-mediated diseases, for $52.50 per share in
Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion
11:10am, Wednesday, 19'th Aug 2020
J&J will buy Momenta Pharmaceuticals for roughly $6.5 billion in cash, paving the way for its Janssen unit to expand its efforts into autoimmune disease treatments.
Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson
10:42am, Wednesday, 19'th Aug 2020
Shares of Momenta Pharmaceuticals Inc. rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by Johnson & Johnson i
Johnson & Johnson to buy Momenta for about $6.5 billion
10:40am, Wednesday, 19'th Aug 2020
The deal gives Johnson & Johnson's Janssen unit access to Momenta's experimental therapy, nipocalimab, being tested for myasthenia gravis, a neuromuscular disease that causes weakness in muscles. "Ni
Momenta Enters Definitive Agreement with Johnson & Johnson
10:34am, Wednesday, 19'th Aug 2020
* Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020 * Momenta’
Why Immunovant Could Benefit From The J&J-Momenta Deal
12:00am, Wednesday, 19'th Aug 2020
Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move.
What Happened: Shares of New York-based Immunovant, which focuses on treatment for...
Insider Selling: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Sells $425,750.00 in Stock
01:54am, Tuesday, 11'th Aug 2020
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Steven C. Gilman sold 13,000 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $32.75, for a
Here's Why Momenta Pharmaceuticals Dropped 13.5% Today
12:21am, Tuesday, 11'th Aug 2020
Without any meaningful revenue, Momenta Pharmaceuticals' (NASDAQ: MNTA) second-quarter report was rather uneventful, so it's a little surprising to see shares down 13.5% today without any significant
Momenta Pharmaceuticals Inc (MNTA) Q2 2020 Earnings Call Transcript
05:00pm, Monday, 10'th Aug 2020
MNTA earnings call for the period ending June 30, 2020.
